AAAzura Mohd Affandi

Azura Mohd Affandi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Azura Mohd Affandi has a total of 64 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Current Management and Unmet Needs in Alopecia Areata: Viewpoint From a Malaysian Perspective

    by Azura Mohd Affandi, Adawiyah Jamil, Noor Zalmy Azizan, Felix Boon-Bin Yap, Kin Fon Leong, Agnes Yoke Hui Heng, Siti Nuraihan, Wooi Chiang Tan, Latha Selvarajah, Teeba Raja, et al.

    Alopecia areata (AA) is a chronic, immune-mediated disease characterized by nonscarring hair loss and a substantial clinical and psychosocial burden, yet it is still widely perceived as a purely cosmetic concern. In this viewpoint, we draw on the available Malaysian studies, selected international evidence, and our collective clinical experience to propose that AA warrants greater clinical, research, and policy attention in Malaysia. Malaysia-specific evidence remains limited and is derived largely from retrospective, single-center studies; nonetheless, the available data point to variable disease presentation, inconsistent use of standardized severity assessment, reliance on conventional therapies, substantial loss to follow-up, and a meaningful psychosocial impact among affected patients. Current local management appears to rely mainly on conventional therapies, while access to advanced therapies such as Janus kinase inhibitors remains constrained by affordability and reimbursement challenges. We therefore call for 5 priorities: strengthening Malaysia-specific epidemiological and real-world evidence, including through a national AA registry; adopting standardized disease-assessment tools in clinical studies and routine practice; integrating psychosocial support into AA care pathways; developing locally relevant clinical guidance; and improving public, clinician, and policymaker awareness that AA is a medical condition rather than a cosmetic concern. Together, these steps would support earlier diagnosis, more equitable access to effective treatment, and holistic, patient-centered care for adults and children living with AA in Malaysia.

  • Open Access

    Bridging Gaps in Malaysian Acne Vulgaris Guidelines: Advisory Statements on Trifarotene for Facial and Truncal Acne

    by Azura Mohd Affandi, Peter Wee Beng Ch'NG, Benji Tze Yuen Teoh, Evelyn Wen Yee Yap, Chin Chwen Ch'NG, Seow Hoong Foo, Kang Nien How, Zhenli Kwan, Jyh Jong Tang, Wooi Chiang Tan, et al.

    Background: Trifarotene, a fourth‐generation topical retinoid, offers a novel therapeutic option for facial and truncal acne. However, its role was only briefly addressed in Malaysia's 2022 Clinical Practice Guidelines (CPGs) due to its unavailability at the time. This paper aims to provide expert advisory statements on the integration of trifarotene into acne management in Malaysia, addressing evidence gaps in guideline coverage, particularly for truncal acne and acne‐induced sequelae. Methods: A literature review was conducted to synthesize evidence on trifarotene's efficacy, safety, and clinical positioning. An advisory panel of 10 Malaysian dermatologists reviewed the evidence and provided consensus through structured surveys and discussion meetings. Three illustrative case studies were included to demonstrate the real‐world application of trifarotene. Results: Ten advisory statements were finalized, addressing trifarotene's role in acne algorithms, patient selection, dosing strategies, combination therapy, and management of acne sequelae. Evidence supports its use for both facial and truncal acne, with additional benefits in acne‐induced hyperpigmentation and atrophic scarring. The panel recommended practical approaches to optimize tolerability and adherence, such as the CTMP (Cleanse‐Treat‐Moisturize‐Photoprotect) regimen and incremental application strategies. Real‐world cases demonstrated trifarotene's utility in diverse clinical settings. Conclusion: These advisory statements provide clinical guidance on the use of trifarotene in Malaysia and support its integration into routine acne management. As current CPGs may remain unchanged in the near term, these recommendations aim to inform evidence‐based practice while bridging gaps in local dermatologic care.


  • Open Access

    Asia‐Pacific consensus recommendations on the management of generalized pustular psoriasis

    by Siew Eng Choon, Peter Anthony Foley, Pravit Asawanonda, Hideki Fujita, Seong‐Jin Jo, Yu‐Ling Shi, Colin Theng, Azura Mohd Affandi, Chul Hwan Bang, Maria Lorna Frez, et al.

    Generalized pustular psoriasis (GPP) is a rare, chronic, heterogeneous, and potentially life‐threatening disease characterized by primary, sterile, and macroscopically visible pustules with or without systemic symptoms. There are ethnic differences in the genetic mutations associated with GPP that might affect the clinical manifestations and treatment responses. Currently, there is limited evidence from the patient population in the Asia‐Pacific (APAC) region, resulting in a general paucity of information on the effective management of patients with GPP in this region. This modified Delphi panel study aimed to identify current evidence and gain advanced insights to facilitate the development of a regionally tailored APAC consensus on the management of GPP. A systematic literature review (SLR) was conducted to identify published literature and develop consensus statements on (i) definition and clinical course, (ii) diagnosis of GPP, (iii) treatment outcomes, goals, and monitoring measures, and (iv) optimal management strategies and clinical practices. Statements were rated by a panel of dermatologists in two rounds, with the threshold for consensus at ≥80% agreement. Twenty experts from the APAC region reached consensus on 106 statements that were developed based on the SLR and experts' collective expertise. The experts agreed that GPP is a rare, severe, and potentially life‐threatening condition that is distinct from plaque psoriasis. This consensus emphasized the importance of a tailored treatment strategy taking into account the GPP flare severity and each patient's unique clinical circumstances. The experts reached consensus on the severity classification of GPP flares and recommended first‐line and maintenance treatment options for adult GPP, childhood GPP, and GPP in pregnancy. These consensus outcomes have been synthesized into treatment algorithms to guide dermatologists in the APAC region in their clinical decision‐making processes.


  • Open Access

    Patient perspective on psoriasis: Psychosocial burden of psoriasis and its management in Malaysia

    by Azura Mohd Affandi, K Thiruchelvam

    Background: Psoriasis is a chronic erythematous inflammatory skin disorder. The major challenge with psoriasis is delayed diagnosis, resulting in delayed treatment initiation and reduced quality of life (QoL). Objective: This patient perspective study aimed to explore the emotional and psychosocial burdens faced by patients with psoriasis in Malaysia and their attitudes toward current psoriasis treatment. Methods: Adult patients with mild or moderate-to-severe plaque psoriasis, preferably with concomitant psoriatic arthritis, participated in a patient advisory board meeting along with a senior consultant dermatologist. Patients had to describe their initial symptoms, time of diagnosis, misdiagnosis, treatment initiation delays, treatment course, flare-ups, psychosocial impact, and QoL associated with psoriasis. Results: The 11 participating patients had a mean age of 46 years with mean age of psoriasis diagnosis and an average year of suffering with psoriasis being 21.9 years and 24.5 years, respectively. The most common initial symptom of psoriasis was itching (62.5%), particularly of the scalp followed by itchiness and red patches on skin. Most patients (90%) reported initial misdiagnosis with other skin diseases by their primary care physicians (PCPs), which led to delayed treatment initiation. Most patients reported an emotional impact of psoriasis, including low self-esteem (18%), lack of confidence (27%), shock (18%), sadness (9%), and outrage (9%). Social discrimination/stigmatization in public places and at work (45%), and even from relatives (18%) was another reported challenge. However, 73% of patients were highly satisfied with the current treatment. Overall, the patients agreed that the lack of public awareness of psoriasis was responsible for the social stigma. Conclusions: The evidence obtained from this qualitative study indicated that psoriasis has a significant emotional and psychological impact on the patients affecting their QoL. Lack of awareness of the disease among PCPs, patients, and the public is a major challenge leading to poor treatment outcomes.


  • Open Access

    Role of Moisturisers in Atopic Dermatitis: Expert Group Recommendations from a Malaysian Panel via Modified Delphi Consensus Method

    by Azura Mohd Affandi, Kang Nien How, Zhenli Kwan, Felix Boon-Bin Yap, Chin Chwen Chng, Wooi Chiang Tan, Evelyn Wen Yee Yap, Latha Selvarajah, Teeba Raja, Khen Meng Kon

    Atopic dermatitis (AD) is a chronic inflammatory skin condition, characterised by dry skin, pruritus and recurrent eczematous lesions. Challenges in the management of AD include fear associated with the use of corticosteroids, compliance issues and frequent flare-ups impacting the quality of life. Moisturisers are the cornerstone of AD management. In this study, we aim to develop the evidence-based consensus recommendations regarding the role and choice of moisturisers for AD. An electronic search of the PubMed/MEDLINE and Cochrane Library was undertaken to identify the relevant articles using keywords such as ‘atopic dermatitis’, ‘eczema’, ‘moisturiser’, ‘humectant’, ‘occlusive’, ‘emollient’, ‘selection’, ‘ingredients’, ‘efficacy’, ‘safety’, ‘formulation’, ‘paediatric’, ‘adult’, ‘prevention’ and ‘guidelines’. A modified Delphi consensus methodology was used to achieve the consensus. A committee of nine dermatologists from Malaysia constituted the panel. Twenty-five questions belonging to five domains were drafted: (i) challenges impacting the regular use of moisturisers in AD; (ii) selection criteria; (iii) role of bioactive ingredients in alleviating AD symptoms; (iv) clinical effectiveness of moisturisers and (v) early initiation of moisturisers for AD prevention. Consensus was set a priori as a minimum agreement of 80%. The panel agreed that moisturisers for AD management should contain humectants, occlusives and emollients to replenish epidermal lipids, retain moisture, reduce inflammation and restore skin barrier function. Regular moisturisation decreases flare-ups and enhances the effectiveness of topical corticosteroids. The experts recommended selecting moisturisers tailored to patient needs, considering factors such as the intensity of skin dryness, site of application, formulation, active ingredients, environmental humidity, climate and cost.


  • Open Access

    Hidradenitis Suppurativa in Kuala Lumpur, Malaysia: A 7-Year Retrospective Review

    by Moonyza Akmal Ahmad Kamil, Azura Mohd Affandi

    Introduction. Hidradenitis Suppurativa (HS) is a chronic inflammatory skin condition characterized by inflamed nodules, abscesses, sinus tracts, and scarring, which can occur in any skin containing folliculopilosebaceous units. We aim to identify the demographic and clinical characteristics and treatment modalities in patients with HS. Methods. A retrospective analysis involving records of patients diagnosed with HS in Hospital Kuala Lumpur from July 2009 to June 2016. Results. Sixty-two patients were identified, with equal cases involving males and females. Majority of patients were Malays (41.9%), followed by Indians (35.5%), Chinese (17.7%), and other ethnicities (4.8%). Median age at diagnosis was 25 (IQR: 14) years. There is a delay in diagnosis with a median of 24 (IQR: 52) months. Most of the patients had lesions on the axilla (85.5%), followed by groin (33.9%) and gluteal region (29%). Gluteal lesions were more common in males. Nodules (67.7%), sinuses (56.5%), and abscesses (33.9%) were the main clinical features, with 43.5% classified under Hurley stage 2. There was no difference in terms of symptoms and types of lesions among different ethnicities and genders. Majority received systemic antibiotics, more than half had retinoid, and third of the patients had surgical intervention. Conclusions. A prompt recognition of HS is imperative, to screen for comorbidities and to initiate early treatment to reduce physical and psychological complications.


  • Open Access

    Epidemiology and Clinical Features of Adult Patients with Psoriasis in Malaysia: 10-Year Review from the Malaysian Psoriasis Registry (2007–2016)

    by Azura Mohd Affandi, Iman Khan, Nooraishah Ngah Saaya

    Background.Psoriasis is a chronic inflammatory skin disease affecting 2-3% of the general population.Aim.To evaluate the epidemiology and clinical characteristics of patients with psoriasis who seek treatment in outpatient dermatology clinics throughout hospitals in Malaysia.Materials and Methods.Data were obtained from the Malaysian Psoriasis Registry (MPR). All patients (aged 18 and above) who were notified to the registry from July 2017 to December 2017 were included in this study.Results.Among 15,794 patients, Malays were the most common (50.4%), followed by Chinese (21.4%), Indian (17.6%), and others (10.6%). The mean age onset of psoriasis for our study population was 35.14 ± 16.16 years. Male to female ratio was 1.3 : 1. 23.1% of patients had positive family history of psoriasis. The most common clinical presentation was chronic plaque psoriasis (85.1%), followed by guttate psoriasis (2.9%), erythrodermic psoriasis (1.7%), and pustular psoriasis (1.0%). Majority of our patients (76.6%) had a mild disease with BSA < 10%. 57.1% of patients had nail involvement, while arthropathy was seen in 13.7% of patients. Common triggers of the disease include stress (48.3%), sunlight (24.9%), and infection (9.1%). Comorbidities observed include obesity (24.3%), hypertension (25.6%), hyperlipidemia (18%), diabetes mellitus (17.2%), ischaemic heart disease (5.4%), and cerebrovascular disease (1.6%). The mean DLQI (Dermatology Life Quality Index) was 8.5 ± 6.6. One-third (33.1%) of the patients had a DLQI score of more than 10, while 14.2% of patients reported no effect at all.Conclusion.Our study on the epidemiological data of adult patients with psoriasis in Malaysia showed a similar clinical profile and outcome when compared to international published studies on the epidemiology of psoriasis.


  • Gemcitabine and vinorelbine treatment in cutaneous T‐cell lymphoma in four patients

    by Azura Mohd Affandi, Tatiana Pinto Blumetti, Jillian Wells, Mark Hertzberg, Pablo Fernandez‐Peñas

    Treatment options for advanced stage cutaneous T‐cell lymphoma (CTCL) are limited by the their efficacy and side‐effects profile. Gemcitabine, a pyrimidine analogue, has been reported to be efficacious in CTCL. Most of the studies published used gemcitabine as a single agent in treating advanced CTCL. Our small case series demonstrated that a combination of gemcitabine and vinorelbine induced partial remission in all four patients with refractory or advanced CTCL, although the effects were not sustained for a long duration (2–6 months). Two patients had neutropenia and one had acute hepatitis, requiring discontinuation of treatment.


  • Non-evolving linear facial plaque

    by A. Mohd Affandi, R. Anforth, S. Chou, P. Fernadez-Peñas